Novartis is one of 73 companies included in the 2017 Water A List by CDP, the nonprofit global environmental disclosure platform.
The third Novartis Social Business stakeholder dialogue took place on November 21 in Basel.
RAND Corporation and the Moran Company issued reports discussing the cost savings associated with biosimilars.
The event will take place on November 21 in Basel.
Individualized CAR‑T therapy uses a patient’s own immune system to fight certain types of cancers.
Newly released survey findings shed light on the daily challenges associated with cataracts and the emotional benefits of improved vision after surgery. Nearly all survey respondents said they would recommend cataract surgery based on their personal experiences.
More than 300 million people live with asthma globally, and 6 million do not adequately control their symptoms. In a new European survey of nearly 1,000 severe asthma patients, 88% reported the condition impacted their daily lives, and almost the same amount (84%) said asthma limited their physical activity.
Jay Bradner, President of the Novartis Institutes for BioMedical Research (NIBR) and Vas Narasimhan, Head of Global Drug Development and Chief Medical Officer, share their outlook for innovation in 2017.
Review the strategy and annual performance of Novartis and read letters from our Chairman and CEO.
This site is intended for a global audience.